Implications of PDE4 structure on inhibitor selectivity across PDE families

被引:21
作者
Ke, H [1 ]
机构
[1] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
关键词
phosphodiesterase inhibitors; PDE4; sildenafil; rolipram; 3; 5 '-cyclic-nucleotide phosphodiesterase; protein conformation; binding sites;
D O I
10.1038/sj.ijir.3901211
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Phosphodiesterases (PDEs) control cellular concentrations of cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). PDE4 and PDE5 selectively hydrolyze cAMP and cGMP, respectively. PDE family members share approximately 25% sequence identity within a conserved catalytic domain of about 300 amino acids. Crystal structure analysis of PDE4's catalytic domain identifies two metal-binding sites: a high-affinity site and a low-affinity site, which probably bind zinc (Zn2+) and magnesium (Mg2+), respectively. Absolute conservation among the PDEs of two histidine and two aspartic acid residues for divalent metal binding suggests the importance of these amino acids in catalysis. Although active sites of PDEs are apparently structurally similar, PDE4 is specifically inhibited by selective inhibitors such as rolipram, while PDE5 is preferentially blocked by sildenafil. Modeling interactions of the PDE5 inhibitor sildenafil with the PDE4 active site may help explain inhibitor selectivity and provide useful information for the design of new inhibitors.
引用
收藏
页码:S24 / S27
页数:4
相关论文
共 16 条
[1]   PURIFICATION AND PROPERTIES OF PERIPLASMIC 3'/5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE - A NOVEL ZINC-CONTAINING ENZYME FROM THE MARINE SYMBIOTIC BACTERIUM VIBRIO-FISCHERI [J].
CALLAHAN, SM ;
CORNELL, NW ;
DUNLAP, PV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (29) :17627-17632
[2]   The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil [J].
de Tejada, IS ;
Angulo, J ;
Cuevas, P ;
Ferndández, A ;
Moncada, I ;
Allona, A ;
Lledó, E ;
Körschen, HG ;
Niewöhner, U ;
Haning, H ;
Pages, E ;
Bischoff, E .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2001, 13 (05) :282-290
[3]   Molecular docking of competitive phosphodiesterase inhibitors [J].
Dym, O ;
Xenarios, I ;
Ke, HM ;
Colicelli, J .
MOLECULAR PHARMACOLOGY, 2002, 61 (01) :20-25
[4]  
FRANCIS SH, 1994, J BIOL CHEM, V269, P22477
[5]  
HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27
[6]   The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis [J].
Huai, Q ;
Colicelli, J ;
Ke, HM .
BIOCHEMISTRY, 2003, 42 (45) :13220-13226
[7]   Three-dimensional structures of PDE4D in complex with roliprams on inhibitor selectivity [J].
Huai, Q ;
Wang, HC ;
Sun, YJ ;
Kim, HY ;
Liu, YD ;
Ke, HM .
STRUCTURE, 2003, 11 (07) :865-873
[8]   The next generation of PDE4 inhibitors [J].
Huang, Z ;
Ducharme, Y ;
Macdonald, D ;
Robichaud, A .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) :432-438
[9]   Crystal structure of phosphodiesterase 4D and inhibitor complex [J].
Lee, ME ;
Markowitz, J ;
Lee, JO ;
Lee, H .
FEBS LETTERS, 2002, 530 (1-3) :53-58
[10]   Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A [J].
Omburo, GA ;
Jacobitz, S ;
Torphy, TJ ;
Colman, RW .
CELLULAR SIGNALLING, 1998, 10 (07) :491-497